These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12559643)

  • 1. Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization.
    Wheatley K; Clayton D
    Control Clin Trials; 2003 Feb; 24(1):66-70. PubMed ID: 12559643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More on data monitoring and large apparent treatment effects.
    Anderson JR
    Contemp Clin Trials; 2005 Jun; 26(3):416-7. PubMed ID: 15911475
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.
    Burnett AK; Goldstone AH; Stevens RM; Hann IM; Rees JK; Gray RG; Wheatley K
    Lancet; 1998 Mar; 351(9104):700-8. PubMed ID: 9504514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.
    Gibson BE; Wheatley K; Hann IM; Stevens RF; Webb D; Hills RK; De Graaf SS; Harrison CJ
    Leukemia; 2005 Dec; 19(12):2130-8. PubMed ID: 16304572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trials stopped early for benefit: a systematic review.
    Montori VM; Devereaux PJ; Adhikari NK; Burns KE; Eggert CH; Briel M; Lacchetti C; Leung TW; Darling E; Bryant DM; Bucher HC; Schünemann HJ; Meade MO; Cook DJ; Erwin PJ; Sood A; Sood R; Lo B; Thompson CA; Zhou Q; Mills E; Guyatt GH
    JAMA; 2005 Nov; 294(17):2203-9. PubMed ID: 16264162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early stopping rules in oncology: considerations for clinicians.
    Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
    Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
    Stevens RF; Hann IM; Wheatley K; Gray RG
    Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triangular test and randomized trials: practical problems in a small cell lung cancer trial.
    Pignon JP; Tarayre M; Auquier A; Arriagada R; Le Chevalier T; Ruffié P; Rivière A; Monnet I; Chomy P; Tuchais C
    Stat Med; 1994 Jul 15-30; 13(13-14):1415-21. PubMed ID: 7973221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.
    Webb DK; Wheatley K; Harrison G; Stevens RF; Hann IM
    Leukemia; 1999 Jan; 13(1):25-31. PubMed ID: 10049056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for children with medulloblastoma.
    Michiels EM; Schouten-Van Meeteren AY; Doz F; Janssens GO; van Dalen EC
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD006678. PubMed ID: 25879092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early stopping rules--clinical perspectives and ethical considerations.
    Baum M; Houghton J; Abrams K
    Stat Med; 1994 Jul 15-30; 13(13-14):1459-69; discussion 1471-2. PubMed ID: 7973225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring of large randomised clinical trials: a new approach with Bayesian methods.
    Parmar MK; Griffiths GO; Spiegelhalter DJ; Souhami RL; Altman DG; van der Scheuren E;
    Lancet; 2001 Aug; 358(9279):375-81. PubMed ID: 11502318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.